MORE►
cancer research
Left: Daniel Hargrove, co-founder and CEO of InterAct Therapeutics; Right: Isaac Chan, MD, PhD, Co-founder and CSO of InterAct Therapeutics [Photos: LinkedIn]
UTSW Spinout InterAct Therapeutics Selected by Cell & Gene Therapy Incubator Program
by Sandra Engelland | Dec 11, 2025
InterAct, which launched inside BioLabs at Pegasus Park, is a preclinical stage biotech company developing AAV8-based gene therapies for metastatic cancer, with an initial focus on breast cancer-derived liver metastases.
by Dallas Innovates | Staff Report |
Dec 5, 2025
The Cancer Prevention & Research Institute of Texas offers funding opportunities for promising cancer research, product development, and prevention programs. The state-funded initiative stands as the second-largest public backer of cancer research in the U.S. after the National Cancer Institute.
MORE►
by Lance Murray |
Jul 2, 2025
UTA and UT Southwestern researchers have built BIT, a new computational framework that helps scientists identify the proteins that switch genes on and off in cancer and other diseases. The work could pave the way to more targeted treatments and boost gene research accuracy.
MORE►
Michael Lunceford, president of the Mary Kay Ash Foundation board of directors. [Photo: Sunwest Communications]
Mary Kay Ash Foundation Awards $2.4M in Cancer Research and Domestic Violence Shelter Grants
by Lance Murray | Oct 16, 2024
That brings to more than $96 million the amount the foundation has given since 1996 to support its two-fold mission: eliminating women-related cancers and ending domestic violence.
MORE►
by Lance Murray |
Sep 17, 2024
Texas Rangers first baseman Nathaniel Lowe leads a star-studded sports team of players and legends from the Dallas Cowboys, Dallas Stars, Dallas Mavericks, FC Dallas, and Dallas Wings in encouraging even more donations on North Texas Giving Day.
MORE►
by Lance Murray |
Jun 17, 2024
Researchers at Children's Hospital of Philadelphia and UT Southwestern analyzed T-cell receptors in nearly 500 blood samples from pre-diagnostic patients with ovarian cancer. The results point to the potential of testing for biomarkers 2 to 4 years before most cases of HGOC are currently diagnosed.
MORE►
by Lance Murray |
Nov 6, 2023
The gift, the largest to date for BrightEdge, will fund a "first-of-its-kind program" called the ACS BrightEdge Texas Accelerator. The two-year pilot innovation program will invest in cutting-edge companies making headway in the fight to eliminate cancer.
MORE►
Michael Bergel, Ph.D., with the structure of his team's patented anti-cancer compounds. Photo by Michael Modecki.
TWU Biology Team Granted a Patent for Anti-Cancer Compounds That Could Save Lives
by Alex Edwards | Oct 15, 2020
The novel invention from researchers at Texas Woman’s University in Denton could greatly contribute to cancer treatment research. The compounds can prevent the growth of breast, lung, and colon cancer cells.
MORE►
by Nicholas Sakelaris |
Nov 28, 2016
The Dallas medical center received $5.8 million from the Cancer Prevention and Research Institute of Texas to fight cancer and attract new researchers.
MORE►
by Nealie Sanchez |
Sep 19, 2016
Its drug therapy for advanced or metastatic clear cell kidney cancer is in phase 1 clinical trials at UT Southwestern.
MORE►
by Julia Falcon |
Jun 29, 2016
UTD has received money for its cancer research program, the Dallas Public Library receives Knight News award, and Facebook adds a simpler way to plan events.
MORE►
